Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Arcutis Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 12 filings
- 5 insiders, $2.30M in total
- Insiders trading
- 5
- Net value
- −$2.30M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Arcutis Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Matsuda Masaru | See Remarks | 112,508 | Sep 18, 2026 | 9 |
| Welgus Howard G. | Director | 35,841 | Sep 17, 2026 | 13 |
| Curran Terrie | Director | 23,526 | Aug 28, 2026 | 3 |
| Burnett Patrick | See Remarks | 117,592 | Aug 21, 2026 | 12 |
| Watanabe Todd Franklin | See Remarks | 717,203 | Aug 5, 2026 | 8 |
| Peetz Christopher | Director | 4,315 | Jul 17, 2026 | 1 |
| Lin Sue-Jean | Director | 27,567 | Jun 17, 2026 | 3 |
| Heron Patrick J | Director | 32,213 | Jun 12, 2026 | 1 |
| Leonard Keith R | Director | 27,901 | Jun 9, 2026 | 3 |
| Gilbert Halley E | Director | 27,901 | Jun 9, 2026 | 2 |
| Munshi Amit | Director | 9,799 | Jun 9, 2026 | 2 |
| Krishnamohan Neha | Director | 27,901 | Jun 9, 2026 | 2 |
| Vairavan Latha | SVP Chief Financial Officer | 85,978 | May 13, 2026 | 5 |
| Edwards Larry Todd | See Remarks | 175,178 | Mar 3, 2026 | 4 |
| Chaudhuri Bhaskar | Director | 867,826 | Jun 16, 2025 | 0 |
| Topper David Joseph | Chief Financial Officer | 182,774 | Apr 3, 2025 | 0 |
| Moore Matthew Richard | SVP and Chief Business Officer | 145,505 | May 3, 2024 | 0 |
| Smither John W | Chief Financial Officer | 11,365 | Feb 15, 2024 | 0 |
| Topper James N | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| Frazier Life Sciences VIII, L.P. | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| FHM Life Sciences VIII, L.P. | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| FHM Life Sciences VIII, L.L.C. | 10% Owner | 8,764,232 | Oct 26, 2023 | 0 |
| Osborne David W | Chief Technical Officer | 268,854 | Mar 8, 2023 | 0 |
| Turney Patricia A. | SVP, Operations | 62,862 | Mar 8, 2023 | 0 |
| Lock Kenneth A. | Chief Commercial Officer | 63,429 | Mar 8, 2023 | 0 |
| Burrows Scott L | Chief Financial Officer | 59,115 | Mar 8, 2023 | 0 |
| OrbiMed Advisors LLC | 10% Owner | 415,142Indirect | Jun 28, 2022 | 0 |
| OrbiMed Capital LLC | 10% Owner | 415,142Indirect | Jun 28, 2022 | 0 |
| OrbiMed Capital GP VII LLC | 10% Owner | 415,142Indirect | Jun 28, 2022 | 0 |
| Turner Joseph L | Director | 4,312 | Jun 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 (view filing) | May 11 | 2 days | Vairavan LathaSVP Chief Financial Officer | SSale | −435 | $21.05 | −$9.16K | −0.5%86.0K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15-17 | 2 days | Welgus Howard G.Director | SSale | −4.73K | $24.58 | −$116.3K | −11.1%37.7K after | 2 lots10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Lin Sue-JeanDirector | SSale | −4.95K | $24.38 | −$120.6K | −15.2%27.6K after | 10b5-1 |
| Jul 17, 2026 (view filing)4:01 PM ET | Jul 15 | 2 days | Welgus Howard G.Director | SSale | −4.73K | $26.91 | −$127.3K | −11.3%37.1K after | 10b5-1 |
| Aug 5, 2026 (view filing)9:42 PM ET | Aug 3 | 2 days | Watanabe Todd FranklinSee Remarks | SSale | −4.38K | $26.12 | −$114.3K | −0.6%717.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)9:42 PM ET | Aug 3 | 2 days | Matsuda MasaruSee Remarks | SSale | −1.23K | $26.12 | −$32.1K | −1.0%126.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)9:42 PM ET | Aug 3 | 2 days | Burnett PatrickSee Remarks | SSale | −955 | $26.12 | −$24.9K | −0.8%119.3K after | 10b5-1 |
| Aug 13, 2026 (view filing)8:06 PM ET | Aug 11-12 | 2 days | Burnett PatrickSee Remarks | SSale | −15.0K | $26.33 | −$394.9K | −11.2%119.3K after | 2 lots |
| Aug 19, 2026 (view filing)4:57 PM ET | Aug 17 | 2 days | Welgus Howard G.Director | SSale | −4.73K | $26.18 | −$123.8K | −11.5%36.5K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:08 PM ET | Aug 19 | 2 days | Burnett PatrickSee Remarks | SSale | −1.70K | $27.00 | −$45.8K | −1.4%117.6K after | |
| Aug 24, 2026 (view filing)4:19 PM ET | Aug 20 | 4 days | Curran TerrieDirector | SSale | −1.07K | $26.04 | −$27.9K | −4.4%23.5K after | |
| Aug 28, 2026 (view filing)5:40 PM ET | Aug 27 | 1 day | Curran TerrieDirector | SSale | −38.2K | $25.03 | −$956.1K | −61.9%23.5K after | 2 lots |
| Sep 10, 2026 (view filing)7:24 PM ET | Sep 8 | 2 days | Matsuda MasaruSee Remarks | SSale | −9.99K | $25.03 | −$250.0K | −7.9%116.2K after | 10b5-1 |
| Sep 17, 2026 (view filing)4:06 PM ET | Sep 15 | 2 days | Welgus Howard G.Director | SSale | −4.73K | $24.18 | −$114.4K | −11.7%35.8K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:17 PM ET | Sep 16 | 2 days | Matsuda MasaruSee Remarks | SSale | −3.67K | $25.00 | −$91.9K | −3.2%112.5K after | 10b5-1 |